angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Blixeprodil, also known by its developmental code name GM-1020 or as (R)-4-fluorodeschloroketamine ((R)-4-FDCK), is an NMDA receptor antagonist related to ketamine which is under development for the treatment of major depressive disorder, bipolar depression, and other depressive disorders. It is taken by mouth.
1 February – Billy Galligan, 86, hurler (Charleville, Blackrock, Claughaun, Avondhu, Cork senior team). 6 February – Niamh Bhreathnach, 77, politician, TD (1992–1997), Minister for Education (1993–1994 and 1994–1997). 7 February – Richard Kell, 95, poet, composer and teacher. 11 February – Séamus Ryan, hurler (Cappamore, Limerick senior team). 12 February James Flynn, 57, film and television producer (Vikings, The Last Duel, The Banshees of Inisherin). Theo Dunne, 85, footballer (Shelbourne) and manager (UCD). 13 February – Deirdre Purcell, 77, actress, journalist, broadcaster and author. 18 February – David G. O'Connell, 69, Roman Catholic prelate, Auxiliary Bishop of Los Angeles (2015–2023). 22 February Mick Burns, 85, hurler (Nenagh Éire Óg, Tipperary senior team, Munster). Dermot Kelly, 90, hurler (Claughaun, Limerick senior team, Munster). 24 February – Tom Tierney, 46, rugby union player (Garryowen, Munster, Leicester, national team) and coach (women's national team). 26 February Tony O'Donoghue, 86, athlete and broadcaster. Kieron Wood, 73, barrister, journalist and writer. 28 February Brian O'Brien, 83, rugby union player (Shannon, Munster, national team) and manager (Shannon, Munster, national team). Jimmy Hatton, 88, Gaelic footballer and hurler (Kilcoole, Wicklow senior teams) and referee.
The results showed that the model could be applied to MLC, but better predictive behavior was found with concentrations of surfactant below the CMC, sub-micellar. A final type of model based on molecular properties of a solute is a branch of quantitative structure-activity relationships (QSAR). QSAR studies attempt to correlate biological activity of drugs, or a class of drugs, with structures. The normally accepted means of uptake for a drug, or its metabolite, is through partitioning into lipid bilayers. The descriptor most often used in QSAR to determine the hydrophobicity of a compound is the octanol-water partition coefficient, log P. MLC provides an attractive and practical alternative to QSAR. When micelles are added to a mobile phase, many similarities exist between the micellar mobile phase/stationary phase and the biological membrane/water interface. In MLC, the stationary phase become modified by the adsorption of surfactant monomers which are structurally similar to the membranous hydrocarbon chains in the biological model. Additionally, the hydrophilic/hydrophobic interactions of the micelles are similar to that in the polar regions of a membrane. Thus, the development of quantitative structure-retention relationships (QRAR) has become widespread. Escuder-Gilabert et al. tested three different QRAR retention models on ionic compounds. Several classes of compounds were tested including catecholamines, local anesthetics, diuretics, and amino acids.
Sources: en.wikipedia.org
== Adverse effects == The following adverse events were observed in at least 10% of people who received eteplirsen in trials: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.
==== Women's international friendly matches ==== 22 February – China 0–0 Ireland. 8 April – USA 2–0 Ireland. 11 April – USA 1–0 Ireland. 22 June – Ireland 3–2 Zambia. 6 July – Ireland 0–3 France. 14 July – A friendly pre-World Cup warmup match against Colombia in Brisbane was abandoned after 20 minutes following harsh incidents by the South Americans against Denise O'Sullivan and Ruesha Littlejohn which earned the offenders yellow cards. O'Sullivan went to hospital with an injury inflicted by Colombian Daniela Caracas who said after the match that the Irish players "are little girls" ("Son unas nenas"), and "let them eat shit" ("que coman mierda").
==== Regeneration ==== Once saturated with water, the gel may be regenerated by heating it to about 120 °C (248 °F) for 1–2 hours. Some types of silica gel will "pop" when exposed to enough water. This is caused by breakage of the silica spheres when contacting the water. Regenerating silica gel is important for both economic and environmental reasons. It can be regenerated thermally or chemically. Chemical methods involve the use of desiccating agents or solvents to desorb water from silica gel, though these are generally less practical for routine regeneration. Thermal regeneration can be applied also to packed silica gel beds without opening them, and can be done by conventional heating in an oven at a temperature around 120 °C. Another option for thermal regeneration is by using microwaves to apply heat more evenly and reduce regeneration time compared to conventional ovens, but this process should be tightly controlled to avoid overheating. Yet another option to apply heat is using a solar heater with a compound parabolic concentrator. There are also studies on using ultrasonic waves to remove water molecules from silica gel at 45–90 °C which are lower temperatures than that of conventional heating.
== R == r-selection – radiobiology – receptor (biochemistry) – receptor (immunology) – recombination – Red Queen – redox reaction – redox system – reduction – reflex – Renal corpuscle – repeats – replication bubble – repressor – reproduction – reproductive system – respiration (physiology) – restriction enzyme – retrovirus – reverse genetics – RFLP – Rh blood group system – ribosome – RNA – RNA virus – Robert Koch – root – rough ER – RuBP – Rudolf Steiner –
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.